The phosphorylation of ERK (Figure 4D, left) and expression of IGF1R (Figure 4D, right) was decreased in tumor lysates from SK-N-AS and NB-Eb-C1 xenografts treated with trametinib and ganitumab, indicating that the in vitro mechanisms of action of each of these drugs was preserved in vivo. This evidence concerns the gene MAPK1 and neoplasm.